MedicationDiscountCard.com Makes Diabetes Treatment More Affordable...
Diabetic Patients Can Obtain Discounts of 10%-75% on Lantus and Metformin(PRWeb March 06, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11641461.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 6, 2014 Category: Pharmaceuticals Source Type: news
China Insulin Glargine Market Investigation Report 2018 Forecasts in...
ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Insulin Glargine Market, 2009-2018” to its store.(PRWeb February 28, 2014)Read the full story at http://www.prweb.com/releases/china-insulin-glargine/market-2009-2018/prweb11627530.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 1, 2014 Category: Pharmaceuticals Source Type: news
Merck, Samsung to Develop and Manufacture Diabetes Drug
The companies collaborate to develop, commercialize MK-1293, an insulin glargine candidate for the treatment of type 1 and type 2 diabetes (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 11, 2014 Category: Pharmaceuticals Source Type: news
Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes
Dateline City:
WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA
WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Samsung Bioepis Co., Ltd., announced today that they have expanded their
collaboration with an agreement to develop, manufacture and
commercialize MK-1293, an insulin glargine candidate for the treatment
of patients with type 1 and type 2 diabetes. Phase III clinical studies
in type 1 and type 2 diabetes will begin soon.
Languag...
Source: Merck.com - Corporate News - February 10, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Novel Insulin Cuts Nocturnal Glucose Plunge
(MedPage Today) -- An investigational long-acting insulin lowered blood sugar with fewer nocturnal hypoglycemic events than conventional insulin glargine (Lantus) in patients with difficult-to-control type 2 diabetes, manufacturer Sanofi announced Tuesday. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 3, 2013 Category: Urology & Nephrology Source Type: news
New data backs promise of long-acting Sanofi insulin
An improved version of Sanofi's Lantus diabetes drug is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events. (Source: The Economic Times)
Source: The Economic Times - December 3, 2013 Category: Consumer Health News Source Type: news
New data backs promise of long-acting Sanofi insulin
PARIS (Reuters) - An improved version of Sanofi's diabetes drug Lantus is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events, new late-stage trial data showed on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Insulin in Patients With Diabetes and Declining KidneysInsulin in Patients With Diabetes and Declining Kidneys
How does insulin glargine and insulin detemir dosing change with changing renal function? Therapeutic Advances in Endocrinology and Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Insulin Degludec Once Daily Similar to Insulin GlargineInsulin Degludec Once Daily Similar to Insulin Glargine
Is insulin degludec as effective as insulin glargine in insulin-naive patients? Diabetes Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 20, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Insulin Glargine Not a Cancer Risk (CME/CE)
(MedPage Today) -- Insulin glargine (Lantus) doesn't significantly raise cancer risk compared with "human" insulin, a registry study affirmed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 26, 2013 Category: Hematology Source Type: news
Insulin Glargine and Metabolites During Long-term TherapyInsulin Glargine and Metabolites During Long-term Therapy
New research explores whether insulin glargine or its metabolites have mitogenic effects. Diabetes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 23, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
ADA: Insulin Does Not Hike Cancer Risk (CME/CE)
CHICAGO (MedPage Today) -- The use of insulin glargine (Lantus) is not associated with an increased risk of any cancer in people with diabetes or prediabetes, according to a substudy of the prospective ORIGIN trial. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 26, 2013 Category: Cardiology Source Type: news
Sanofi plans late-stage diabetes combo drug tests in 2014
PARIS (Reuters) - Sanofi aims to start late-stage tests for a pen device combining diabetes treatments Lantus and Lyxumia in the first half of 2014, according to slides posted on its website ahead of a presentation to investors on Monday. (Source: Reuters: Health)
Source: Reuters: Health - June 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Sanofi’s new insulin superior to Lantus: study
Sanofi’s investigational diabetes drug U300 is better at controlling dangerous low blood sugar events at night than its blockbuster Lantus, according to data from a phase III clinical programme. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 23, 2013 Category: Pharmaceuticals Source Type: news
Sanofi's next-generation insulin shows edge over Lantus
PARIS (Reuters) - An improved version of Sanofi's blockbuster insulin Lantus is better than the older drug at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin, according two late-stage tests published on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - June 22, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
